Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
20.35
+0.63 (3.19%)
At close: Nov 3, 2025, 4:00 PM EST
20.40
+0.05 (0.24%)
After-hours: Nov 3, 2025, 4:39 PM EST
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $26.00M in the quarter ending September 30, 2025, a decrease of -45.83%. This brings the company's revenue in the last twelve months to $240.00M, down -8.75% year-over-year. In the year 2024, Arcus Biosciences had annual revenue of $258.00M with 120.51% growth.
Revenue (ttm)
$240.00M
Revenue Growth
-8.75%
P/S Ratio
8.27
Revenue / Employee
$382,775
Employees
627
Market Cap
2.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
RCUS News
- 3 days ago - Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - Business Wire
- 4 days ago - Arcus Biosciences Announces Commencement of Public Offering of Common Stock - Business Wire
- 6 days ago - Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 14 days ago - Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia - Business Wire
- 18 days ago - Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets - Seeking Alpha
- 22 days ago - Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study - Business Wire
- 25 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 27 days ago - Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript - Seeking Alpha